DOCSLIB.ORG

Drug Index and Glossary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Index and Glossary Drug index and glossary Approved name Proprietary name Proprietary name Page (UK) (USA) number Acebutolol Sectral Sectral 101 Acetaminophen (see Paracetamol) Actinomycin Cosmegen Lyovac 21 Acyclovir Zovirax Zovirax 30, 65-6, 156, 159,281 Adenosine triphosphate 233 Adrenaline 72, 78, 262, 263, (epinephrine) 264,265 Alcohol (see Ethanol) Aloes 48 Aluminium hydroxide Alu-Cap Many preparations 90 Aludrox available Ambroxol 39,143 Amikacin Amikin Amikin 29,152,167,168, 184-6,281 Aminophylline Pecram Mudrane 30,39,133,134, Phyllocontin Somophylline 143,283 Continus Theodrox Aminosalicylic acid 154, 168, 198, (para-aminosalicylic 203-4 acid) Amiodarone Cordarone Cordarone 24 Amoxycillin Almodan Trlmox 152, 154, 155, (amoxicillin) Amoxil Wymox 160, 161, 162, 166,167, 171-2, 192, 281 Amphotericin Fungilin 'Fungizone' 168, 207--S, 281 Fungizone Ampicillin Ampifen Omnipen 47,162,16,167, Penbritin Principen 281 Vidopen Unasyn Amylobarbitone Amytal 108,125 (amobarbital) Antitetanus Humotet Hyper-Tet 53,54-5 immunoglobulin Antivaccinial gamma 51,58 globulin Drug index and glossary 289 Approved name Proprietary name Proprietary name Page (UK) (USA) number Antivaricella-zoster 65 immunoglobulin Apomorphine 97 Arnica 278 Ascorbic acid Redoxon Many preparations 70,75--6 available Aspirin Many preparations Many preparations 23,48,99,100, available available 141,272-3,276 Atebrin 12 (Atabrine, Medacrine, Quinacrine) Atenolol Tenormin Tenormin 101,120 Atropine Many combined Many combined 48,49,96,222, preparations preparations 234,250,26S-9 available available Azathioprine Imuran Imuran 32,48 Azlocillin Securopen Azlin 162,281 Belladona alkaloids 90 Benzalkonium Rocca! Amino-Cery 168,210 Cetycide Fungoid Ionil-T Benzathine penicillin Penidural 160,167,171 Benzylpenicillin CrystapenG Pentids 47, 152, 153, 154, (Penicillin G) Pfizerpen 160,162, 166, 167,16S-70, 171,174,230, 282 Bephenium Alcopar 219 Betamethasone Betnelan Celestone 143,144,145 Betnesol Bithionol 221,222 Bromelains 279 Bromethol 105,125 Bromides 49 Bromocriptine Parlodel Parlodel 46,49-50 Bupivacaine Marcain Marcaine 23,261,263, Sensorcaine 2~ Busulphan Myleran Myleran 21 Butobarbitone Soneryl Butisol 10S-9 (Butobarbital) 290 Drug index and glossary Approved name Proprietary name Proprietary name Page (UK) (USA) number Caffeine Many combination Many preparations 283 preparations available available Calciferol 49 (ergocalciferol) Calcium and vitamin 0 4 Calcium channel 10,121 blockers Calcium gIuconate 123-4 Cannabis 40 Captopril Acepril Capoten 10,31 Capoten Carbamazepine Tegretol Tegretol 9,26,27 Carbenicillin Pyopen Geopen 167,175,176,282 Carbimazole Neo-Mercazole 30,46,48 Carboxypenicillin 176 Carfecillin Uticillin 167,175-6 Cascara sagrada 48 Castor oil Many preparations 230 available Cefamandole Kefadol Mandol 29,178 (Cephamandole) Cefmenoxime 163 Cefotaxime Oaforan Claforan 282 Cefotiam 163 Cefoxitin Mefoxin Mefoxin 163,167,175, 178,179,180, 282 Ceftazidime Fortum Fortax 163,282 Tazicef Tazidime Cefizoxime Ceftizox Ceftizox 163 Cefuroxime Kefurox 158, 163, 166, Zinacef Zinacef 167,178,179, 180,282 Cephalexin Ceporex Keflet 167,178,179 Keflex Keflex Cephaloridine 163,178 Cephalothin Keflin Seffin 162, 163, 178 Cephazolin Kefzol 155,163,167, 178,179,180 Cephradine Anspor 163,167,178, Velosef Velocef 179,180 Cetrimide Cetavlon 168,210,212, 229 Many combined preparations Drug index and glossary 291 Approved name Proprietary name Proprietary name Page (UK) (USA) number Chloral betaine Welldorm 113 Chloral hydrate Noctec 112-13,283 Chloramphenicol Chloromycetin Chloromycetin 29,47,73,152, Kemicetin 213,224,281, 282 Chlorambucil Leukeran Leukeran 21 Chlordiazepoxide Librium Libritabs 42,109-10 Librium Librax Limbritol Menrium Chlorhexidine Many preparations Hibiclens 168,210,212, available Hibistat 229,230 Peridex Chlorinated lime 168,210-11 Chlormethiazole Hemineverin 113-15,122,125 Chloroform 105,119 Chloroquine Avlochlor Aralen 12,28,215,216 Nivaquine Chlorothiazide Saluric Diuril 127 Chloroxylenol Dettol Fungoid 168,211,230 Micro-Gard Sween Prep Chlorpromazine Largactil Thorazine 38,49,88,89,96, 104,105, 126 Chlorpropamide Diabinese Diabinese 31 Chlortetracycline Aureomycin Aureomycin 195 Cholera vaccine 51,5~ Cholestyramine Questran Questran 37 Chymotrypsin 278 Cimetidine Tagamet Tagamet 93,94 Ciprofloxacin Ciproxin 168 Clavulanic acid 178 Clindamycin DalacinC Cleocin 47,152, 161, 164, 166, 167, 168, 186-7 Clofazimine Lamprene Lamprene 212 Clofibrate Atromid-S Atromid-S 11,37 Clonidine Catapres Catapres 100,102 Clotrimazole Canestan Gyne-Lotrimin 158, 168, 20~ Mycelex Lotrimin Cloxacillin Orbenin 172,282 Cocaine 41 292 Drug index and glossary Approved name Proprietary name Proprietary name Page (UK) (USA) number Codeine Many combination Many combination 253,275 preparations preparations available available Cortisone Cortelan Cortone 283 Cortistab Cortisyl Co-trimazine 35,47 Co-trimoxazole Bactrim Bactrim 35,47, 152, 156, Septrin Septra 158,160,161, 168,181-3, 217,282 Crack (see Cocaine) Cyanocobalamin Cytacon Many preparations 68,72,81 (Vitamin B12) Cytamen available Cyclopentolate Mydrilate 283 Cyclosporin Sandimmun Sandimmune 32,48 Dapsone 10,29,73,154, 156,212, 213, 216 Debrisoquine Declinax 102 Demeclocycline Ledermycin 195 Demethyl 1% chlortetracycline Dexamethasone Decadron DelaloneDP 143,144--5 Oradexon DecadronLA DexasoneLA Hexadrol Dexamphetamine Dexedrine Dexedrine 40 (Dextroamphetamine) Obetrol Dextropropoxyphene Docoxene Darvon 274--5 (Propoxyphene) Dolene Lorcet Diamorphine 41,143,254-5 (heroin) Diazepam Alupram T-Quil 27,42,49,103, Atensine Valium 104,106, Diazemuls Valrelease 110-11,122, Solis 124--5,226,229 Stesolid Valium Diazoxide Eudemine Hyperstat 31,100,102,125 Proglycem Drug index and glossary 293 Approved name Proprietary name Proprietary name Page (UK) (USA) number Dichloral- 113 phenazone Dicoumarol 24 (dicumarol) Diethylcarbamazine Banocide 218,219,220 Digitalis 39 Digoxin Lanoxin Lanoxicaps 283 Lanoxin Dihydrocodeine DF118 Synalgos-DC 276 Dihydrogenated Hydergine Hydergine 230,231 ergot alkaloids (co-dergocrine) Dihydrotachysterol ATlO DHT 34,49 Tachyrol Diloxanide Furamide 214 Entamizole Dimenhydrinate Dramamine Dramamine 88 Dinoprost (see Prostoglandin F2.) Dinoprostone (see Prostoglandin E2) Disulfiram Antabuse Antabuse 40 Dopamine Intropin Intropin 46,49 Select-A-Jet Doxycycline Nordox Doryx 195,196 Vibramycin Vibramycin Vibramycin-D Enalapril Innovace Vasotec 10 Enema saponis 245-6 Enemata 245-6 Entonox 230,234,255-6 Enzymes 278-9 Epinephrine (see Adrenaline) Ephedrine Broncholate 260 Medicone Mudrane Primatene Quadrinal Ergotamine Cafergot BeIIergal 37 Lingraine Caffergot Medihaler- Medihaler- Ergotamine Ergotamine Migril Wingraine 294 Drug index and glossary Approved name Proprietary name Proprietary name Page (UK) (USA) number Ergometrine 106,234, 240, (Ergonovine) 243-5 Ergometrine with 106, 226, 245 oxytocin Syntometrine Erythromycin Many preparations Many preparations 158, 159,160, available available 167,168, 18S-9,282 Ethambutol Myambutol Myambutol 154, 168, 198, 200-1,204 Ethanol 5,40,45,46,47, 49,113,132, 133,134,168, 191,214 Ether 119 Ethyl chloride 220 Etretinate Tigason Tegison 21 Fenoprofen Fenopron 141 Ferrous fumarate Fersaday Many preparations 70,75 Fersamal available Galfer Ferrous gluconate 70,74 Ferrous gluconate 77 with folic acid Ferrous glycine Plesmet 75 sulphate Ferrocontin Ferrous succinate Ferromyn 75 Ferrous sulphate Feospan Feosol 70,74,283 Ferrograd !beret Slow-Fe Irospan Slow-Fe Ferrous sulphate with Many preparations Many preparations 75-6 ascorbic acid available available Flucloxacillin Floxapen 152,167,172-3, 282 Fluconazole Diflucan 156 Fluoride 48 Fluphenazine Moditen Permitil 34 Prolixin Drug index and glossary 295 Approved name Proprietary name Proprietary name Page (UK) (USA) number Folic add Lexpec Many preparations 8,11,13,14,26, (pterylglutamic available 27,34,35,37, add) 38,47,68,70, 71,72,73, 76--7,80-1, 82,152, 161, 181, 183,217, 219,283 Folinic acid Calcium Leucovorin 28, 154,215, Refolinon 216,217 Frusemide Aluzine Lasix 9,31,71,101, (furosemide) Diuresal 106,127-9,283 Dryptal Lasix Fusidicadd Fuddin 167,168 (see also Sodium fusidate) Gamma benzene Lorexane Kwell 223 hexachloride Quellada Scabene (lindane) Gamma globulin 62-3 Gas gangrene 60,160 antitoxin (mixed) Gemeprost Cervagem 226,235--6 Gentamicin Cidomycin G-Myticin 29, 152, 155, Genticin Garamycin 160, 164, 166, Gentafair 167,168, 183-4, 185,282 Haloperidol Dozic Haldol 115 Fortunan Haldol Serenace Halothane Fluothane Fluothane 133 Hashish (see Cannabis) Heparin Many preparations Embolex 9,16,24,25,46 available Caldparin Hep-Lock Liquaemin 296 Drug index and glossary Approved name Pruprietary name Proprietary name Page (UK) (USA) number HepatitisB HBIG HBIG 59 immunoglobulin Hep-B-Gammagee Hepatitis B vaccine Engerix-B HeptavaxB 59-60 H-B-Vax Recombivax-HB Heroin (see Oiamorphine) Hexachlorophane Sterzac Phisohex 168,211 (hexachlorophene) Human normal 63 immunoglobulin Hydralazine Apresoline Apresoline 37,101,103,104, 105,116-18, 120, 122, 124-5 Hydrocortisone Hydrocortistab Many preparations 72,220 Hydrocortone available Efcortesol Solu-Cortef Hydrogen peroxide 168,211 Hydroxocobalamin CobalinH Alphapedisol 72,81,223 Neo-Cytamen Hydroxyprogesterone Proluton Depot Prodrox250 33 Hyoscine 269 hydrobromide (scopolamine) Hypochlorite Milton 211 (electrolyte) Hypogiycaemic 31,48,119 drugs Ibuprofen Many preparations Many preparations 141 available available Idoxuridine Herpid 30,159 Iduridin Virudox Indomethacin Many preparations Indocin 13,140,
Load more

Recommended publications
  • PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
    PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • ADD/ADHD: Strattera • Allergy/Anti-Inflammatories
    EXAMPLES OF PERMITTED MEDICATIONS - 2015 ADD/ADHD: Strattera Allergy/Anti-Inflammatories: Corticosteroids, including Decadron, Depo-Medrol, Entocort, Solu-Medrol, Prednisone, Prednisolone, and Methylprednisolone Anesthetics: Alcaine, Articadent, Bupivacaine HCI, Chloroprocaine, Citanest Plain Dental, Itch-X, Lidocaine, Marcaine, Mepivacaine HCI, Naropin, Nesacaine, Novacain, Ophthetic, Oraqix, Paracaine, Polocaine, Pontocaine Hydrochloride, PrameGel, Prax, Proparacaine HCI, Ropivacaine, Sarna Ultra, Sensorcaine, Synera, Tetracaine, Tronothane HCI, and Xylocaine Antacids: Calci-Chew, Di-Gel, Gaviscon, Gelusil, Maalox, Mintox Plus, Mylanta, Oyst-Cal 500, Rolaids, and Tums Anti-Anxiety: Alprazolam, Atarax, Ativan, Buspar, Buspirone HCI, Chlordiazepoxide HCI, Clonazepam, Chlorazepate Dipotassium, Diastat, Diazepam, Hydroxyzine, Klonopin, Librium, Lorazepam, Niravam, Tranxene T-tab, Valium, Vistaril, and Xanax Antibiotics: Acetasol HC, Amoxil, Ampicillin, Antiben, Antibiotic-Cort, Antihist, Antituss, Avelox, Ceftazidime, Ceftin, Cefuroxime Axetil, Ceptaz, Cleocin, Cloxapen, Cortane-B Aqueous, Cortic, Cresylate, Debrox, Doryx, EarSol-HC, Fortaz, Gantrisin, Mezlin, Moxifloxacin, Neotic, Otocain, Principen, Tazicef, Tazidime, Trioxin, and Zyvox Anti-Depressants: Adapin, Anafranil, Asendin, Bolvidon, Celexa, Cymbalata, Deprilept, Effexor, Elavil, Lexapro, Luvox, Norpramin, Pamelor, Paxil, Pristiq, Prozac, Savella, Surmontil, Tofranil, Vivactil, Wellbutrin, Zoloft, and Zyban Anti-Diabetics: Actos, Amaryl, Avandia, Glipizide, Glucophage,
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Clinical Trial of Orciprenaline in Bradyarrhythmias
    100 SINGAPORE MEDICAL JOURNAL Vol. 16, No. 2. June, 1975. CLINICAL TRIAL OF ORCIPRENALINE IN BRADYARRHYTHMIAS By Chin Hock, Lirn, Charles C. S. Toh and Oon Teik, Khoo SYNOPSIS The intravenous and oral forms of orciprenaline was used in the treatment of patients with severe sinus bradycardia, high grade atrio -ventricular block or the sick sinus syndrome. Intra- venous orciprenaline can be used to tide patients over a period of severe bradyarrhythmia, or prior to cardiac pacing. One patient developed ventricular tachycardia following an intravenous bolus of orciprenaline. Oral orciprenaline was used in 23 patients with severe bradyarrhythmia. Two patients responded poorly to it. Saventrine was given sequentially in nine patients. The merits and side effects of both drugs are discussed. INTRODUCTION efficiency of orciprenaline and to compare it with Saventrine in the treatment of complete In 1952, Nathanson and Miller introduced heart block and other forms of bradyarrhyth- isoprenaline for the treatment of heart block and mias. it still has an important role in the treatment of bradyarrhythmias. Nis Innissen and Thompson PHARMACOLOGY (1965) felt that the use of a sustained release form of isoprenaline could reduce the need for Orciprenaline (Alupent*) is a derivative of pacemakers. Intravenous isoprenaline and orci- isoprenaline but it has predominant beta -two prenaline may be used to treat patients with stimulatine effects and is commonly used as a Stokes Adams (S.A.) attacks resulting from very bronchodilator (Bogdan, 1969). However, it has slow ventricular rates in acute myocardial chronotropic and inotropic effects. It stimulates infarction, either alone or prior to cardiac the sino -atrial and atrioventricular nodes and pacing.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • UV-Vis-5-Compressed.Pdf
    Ultraviolet and visible spectroscopy David G. Watson Lecture 5 EMADALSAMARRAI Fig.4.13 The complex formed between adrenaline and iron, which is used to analyse adrenaline at low levels in an injection. Adrenaline iron (ll) complex l'iiiitl.iiitiliiiil Self-test 4.7 iiri:lilllr:i!!!f !!:ill Adrenaline in bupivacaine/adrenaline injection is assayed by complex formation with iron (ll). 20 ml of the injection is mixed with 0.2 ml of reagent and 2 ml of buffer and a reading istaken in a 4 cm pathlength cell. A reading of a solution containing 5.21 pglml of adrenaline is taken under the same conditions. The following results were obtained: . Absorbance of sample:0.173 . Absorbance of standard solution:0.18i Calculate the percentage of w/v of adrenaline in the injection. t n/rvr %s000'0 :JaMsuv Difference spectrop hotometry In difference spectroscopy, a component in a mixture is analysed by carrying out a reaction which is selective for the analyte. This could be simply bringing about a shift in wavelength through adjustment of the pH of the solution in which the analyte is dissolved or a chemical reaction such as oxidation or reduction. In the following example the selective alkaline shift of aspirin is used to determine it in a preparation also containing dextropropoxyphene, naphthalene sulphonic acid and caffeine. Caffeine, dextropropoxyphene and the naphthalene sulphonic acid anion do not undergo appreciable alkaline shifts whereas aspirin does. Figure 4.14A shows the spectrum of the extract from tablets in 0.1 M HCI - in fact there is relatively minor interference at the wavelength used for the determination of aspirin but by using the sample in HCI in place of a blank in the reference cell one can be sure that interference from the excipients is eliminated.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Tocolytic Therapy a Meta-Analysis and Decision Analysis
    Tocolytic Therapy A Meta-Analysis and Decision Analysis David M. Haas, MD, MS, Thomas F. Imperiale, MD, Page R. Kirkpatrick, Robert W. Klein, Terrell W. Zollinger, DrPH, and Alan M. Golichowski, MD, PhD OBJECTIVE: To determine the optimal first-line tocolytic ing prostaglandin inhibitors, only 80 would deliver within agent for treatment of premature labor. 48 hours, compared with 182 for the next-best treatment. METHODS: We performed a quantitative analysis of ran- CONCLUSION: Although all current tocolytic agents domized controlled trials of tocolysis, extracting data on were superior to no treatment at delaying delivery for maternal and neonatal outcomes, and pooling rates for both 48 hours and 7 days, prostaglandin inhibitors were each outcome across trials by treatment. Outcomes were superior to the other agents and may be considered the delay of delivery for 48 hours, 7 days, and until 37 weeks; optimal first-line agent before 32 weeks of gestation to adverse effects causing discontinuation of therapy; absence delay delivery. of respiratory distress syndrome; and neonatal survival. We (Obstet Gynecol 2009;113:585–94) used weighted proportions from a random-effects meta- analysis in a decision model to determine the optimal first-line tocolytic therapy. Sensitivity analysis was per- reterm birth, defined as any birth before the gesta- formed using the standard errors of the weighted propor- Ptional age of 37 weeks, is responsible for most of the 1–3 tions. neonatal morbidity and mortality in the United States and consumes 35% of all U.S. healthcare spending on RESULTS: Fifty-eight studies satisfied the inclusion crite- 4 ria.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al
    USOO9376418B2 (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle et al. (45) Date of Patent: Jun. 28, 2016 (54) SUBSTITUTED PYRIDINE SPLEEN 31/5377 (2013.01); A61K3I/5383 (2013.01); TYROSINE KINASE (SYK) INHIBITORS A61 K3I/551 (2013.01); A61K 45/06 (2013.01); C07D401/14 (2013.01); C07D (71) Applicants: Merck Sharp & Dohme Corp., 405/14 (2013.01); C07D 409/14 (2013.01); Rahway, NJ (US); Merck Canada Inc., C07D 413/14 (2013.01); C07D 417/14 Kirkland, Quebec (CA) (2013.01); C07D 471/04 (2013.01); (Continued) Inventors: (72) Andrew M. Haidle, Cambridge, MA (58) Field of Classification Search (US); Sandra Lee Knowles, Princeton, CPC ............... CO7D 401/12: CO7D 401/14: A61 K NJ (US); Solomon D. Kattar, Arlington, 31/5377; A61K31/506 MA (US); Denis Deschenes, Lachine USPC ........................ 544/122, 331; 514/235.8, 275 (CA); Jason Burch, Redwood City, CA See application file for complete search history. (US); Joel Robichaud, Dollard-des-Ormeaux (CA); Matthew (56) References Cited Christopher, Brookline, MA (US); Michael D. Altman, Needham, MA U.S. PATENT DOCUMENTS (US); James P. Jewell, Newtown, MA 5,710,129 A 1/1998 Lynch et al. (US); Alan B. Northrup, Reading, VA 6/2001 Uckun et al. (US); Marc Blouin, Saint-Lazare (CA); 6,248,790 B1 John Michael Ellis, Needham, MA (Continued) (US); Hua Zhou, Acton, MA (US); Christian Fischer, Natick, MA (US); FOREIGN PATENT DOCUMENTS Adam J. Schell, Decatur, GA (US); EP 877O2O A1 11, 1998 Michael H. Reutershan, Brookline, MA EP 2441755 A1 4/2012 (US); Brandon M.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Effects of Ritodrine Hydrochloride, a Beta2-Adrenoceptor Stimulant, on Uterine Motilities in Late Pregnancy
    Japan. J. Pharmacol. 35, 319-326 (1984) 319 Effects of Ritodrine Hydrochloride, a Beta2-Adrenoceptor Stimulant, on Uterine Motilities in Late Pregnancy Shigeru IKEDA, Hiroshi TAMAOKI, Masuo AKAHANE and Yoshifumi NEBASHI Central ResearchLaboratories, Kissei Pharmaceutical Co., Ltd. 19-48 Yoshino,Matsumoto 399-65, Japan Accepted April7, 1984 Abstract•\Ritodrine hydrochloride (ritodrine) is a beta2-adrenoceptor stimulant which has been effectively prescribed for the prevention of premature labor. The present studies were carried out to investigate the effects of ritodrine on uterine motility in rats and rabbits during gestation, as compared with those of isoproterenol and isoxsuprine. The results were as follows: 1) Spontaneous movements and evoked contractile responses of isolated rat uterus (19-20th days of gestation) were suppressed by 10-9-1 0-6 M ritodrine. The potency of ritodrine was approximately 10 times more than that of isoxsuprine and 100-1,000 times less than that of iso- proterenol. 2) When these drugs were administered to pregnant rats or rabbits intravenously, the tocolytic potency was in the following order: isoproterenol> ritodrine>isoxsuprine. 3) Ritodrine induced hypotension and tachycardia, but these effects were less than those of isoproterenol and isoxsuprine. 4) The effects of isoproterenol and ritodrine were almost prevented by pretreatment with pro- pranolol, but those of isoxsuprine were only partially or not affected. These results suggest that ritodrine is effective in preventing the uterine contractions in rats and rabbits and that it has less effect on the circulatory system than isoproterenol and isoxsuprine. It is also concluded that ritodrine produces these effects through activation of beta-adrenoceptors.
    [Show full text]